3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
17
Neoplasms
6
Pancreatic Neoplasms
5
Lung Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
3
Head and Neck Neoplasms
3
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Salivary Gland Neoplasms
1
Rhabdoid Tumor
1
Respiratory Tract Diseases
1
Papillary renal cell carcinoma, sporadic
1
Pancreatic Intraductal Neoplasms
1
Oropharyngeal Neoplasms
1
Neoplasms, Unknown Primary
1
Neoplasms, Squamous Cell
1
Neoplasms, Basal Cell
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Mouth Neoplasms
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
1
Liver Cirrhosis
1
Leiomyosarcoma
1
Laryngeal Neoplasms
1
Kidney Neoplasms
1
Hypopharyngeal Neoplasms
1
Histiocytoma, Malignant Fibrous
1
Hereditary leiomyomatosis and renal cell cancer
1
Interventions
Gemcitabine
33
Cisplatin
28
pembrolizumab
19
durvalumab
17
Oxaliplatin
16
Fluorouracil
16
Leucovorin
14
Magnetic Resonance Spectroscopy
13
Biopsy
10
Specimen Handling
9
lenvatinib
7
Nivolumab
7
Capecitabine
7
Taxes
6
Paclitaxel
6
Irinotecan
6
fludarabine
5
Folfox protocol
5
Drug Therapy
5
Carboplatin
5
Albumin-Bound Paclitaxel
5
pemigatinib
4
Ipilimumab
4
Fluorodeoxyglucose F18
4
Floxuridine
4
Cyclophosphamide
4
Bevacizumab
4
130-nm albumin-bound paclitaxel
4
tremelimumab
3
olaparib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Cholangiocarcinoma
×
Erlotinib Hydrochloride
×
1 year
×
Clear all
No trials found.